Literature DB >> 8605917

Inhibition of thymocyte negative selection by T cell receptor antagonist peptides.

O Williams1, Y Tanaka, M Bix, M Murdjeva, D R Littman, D Kioussis.   

Abstract

The T cell receptor (TCR) recognizes antigenic peptide presented by major histocompatibility complex (MHC) molecules. Analogs of antigenic peptides have been shown to inhibit antigen-specific T cell responses, a phenomenon described as TCR antagonism. We have examined the effect of a natural variant of an antigenic peptide and a synthetic peptide analog, on the responses of mature T cells and immature thymocytes from an alpha-beta TCR-transgenic mouse (F5), the TCR of which recognizes a nonamer peptide from the nucleoprotein (NP) of influenza virus in the context of the H-2Db MHC molecule. Both peptides were shown to antagonize specifically the T cells cytolytic response without being able directly to stimulate mature T cells from these transgenic mice. Furthermore, a negative selection assay in vitro was used to demonstrate for the first time that antagonistic peptides are capable of antagonizing thymocyte deletion induced by antigenic peptides. These data suggest that the final selection of a T cell could be the result of a balance between the positive and negative influences of endogenous peptide ligands.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605917     DOI: 10.1002/eji.1830260305

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Altered positive selection due to corecognition of floppy peptide/MHC II conformers supports an integrative model of thymic selection.

Authors:  Christophe Viret; Xin He; Charles A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-16       Impact factor: 11.205

2.  Interactions with multiple peptide ligands determine the fate of developing thymocytes.

Authors:  O Williams; R Tarazona; A Wack; N Harker; K Roderick; D Kioussis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

3.  Partial signaling by CD8+ T cells in response to antagonist ligands.

Authors:  C Reis e Sousa; E H Levine; R N Germain
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

4.  Inhibition of intrathymic T cell development by expression of a transgenic antagonist peptide.

Authors:  C N Levelt; E Mizoguchi; X Huang; R Zacks; A K Bhan; S Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

5.  High- and low-affinity single-peptide/MHC ligands have distinct effects on the development of mucosal CD8alphaalpha and CD8alphabeta T lymphocytes.

Authors:  C N Levelt; Y P de Jong; E Mizoguchi; C O'Farrelly; A K Bhan; S Tonegawa; C Terhorst; S J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

6.  Altered peptide ligands induce quantitatively but not qualitatively different intracellular signals in primary thymocytes.

Authors:  L A Smyth; O Williams; R D Huby; T Norton; O Acuto; S C Ley; D Kioussis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

7.  Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells.

Authors:  Han Xian Aw Yeang; Junnat M Hamdam; Laith M A Al-Huseini; Swaminathan Sethu; Laiche Djouhri; Joanne Walsh; Neil Kitteringham; B Kevin Park; Christopher E Goldring; Jean G Sathish
Journal:  J Biol Chem       Date:  2012-02-06       Impact factor: 5.157

8.  Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia.

Authors:  G E Price; R Ou; H Jiang; L Huang; D Moskophidis
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

9.  CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self.

Authors:  Rachel E Shrimpton; Matt Butler; Anne-Sophie Morel; Efrem Eren; Swee Shan Hue; Mary A Ritter
Journal:  Mol Immunol       Date:  2009-01-08       Impact factor: 4.407

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.